| Exposure; cancer site | Latency period (range, yr) | Source | Corresponding CCHS cycle (yr) |
|---|---|---|---|
| Active tobacco | |||
| Lung | 7-33 | Boffetta and colleagues 20065 Kenfield and colleagues 20086 Freedman and colleagues 20087 Yun and colleagues 20058 | 1.1 (2000/01) |
| Oral cavity and pharynx | 4-26 | Boffetta and colleagues 20065 Friborg and colleagues 20079 Nordlund and colleagues 199710 | 1.1 (2000/01) |
| Larynx | 4-9 | Jee and colleagues 200411 Freedman and colleagues 20077 Yun and colleagues 20058 | 3.1 (2005) |
| Esophagus | 9-15 | Tran and colleagues 200412 Jee and colleagues 200411 Ishiguro and colleagues 200913 | 1.1 (2000/01) |
| Stomach | 6-8 | Jee and colleagues 200411 Lindblad and colleagues 200514 Sung and colleagues 200715 | 3.1 (2005) |
| Liver | 5-26 | Yang and colleagues 200216 Nordlund and colleagues 199710 Basa and colleagues 197717 | 1.1 (2000/01) |
| Pancreas | 6-23 | Nordlund and colleagues 199710 Friedman and van den Eeden 199318 | 1.1 (2000/01) |
| Colon-rectum | 9-13 | Tsoi and colleagues 200919 Jee and colleagues 200411 Hannan and colleagues 200920 | 1.1 (2000/01) |
| Ovary | 13-23 | Terry and colleagues 200321 Tworoger and colleagues 200822 Gram and colleagues 200823 | 1.1 (2000/01) |
| Cervix | 2-10 | Kapeu and colleagues 200924 McIntyre-Seltman and colleagues 200525 Schiffman and colleagues 199326 | 4.1 (2007) |
| Kidney | 16-27 | Chow and colleagues 200027 Engeland and colleagues 199628 Nordlund and colleagues 199710 | 1.1 (2000/01) |
| Bone marrow (myeloid leukemia) | 19-26 | Fernberg and colleagues 200729 Nordlund and colleagues 199710 Engeland and colleagues 199628 | 1.1 (2000/01) |
| Bladder | 3-26 | Alberg and colleagues 200730 Tulinius and colleagues 199731 Nordlund, 199710 Yuan and colleagues 199632 | 1.1 (2000/01) |
| Passive tobacco | |||
| Lung | 6-13 | Veglia and colleagues 200733 Vineis and colleagues 200534 Kurahashi and colleagues 200835 | 2.1 (2003) |
Note: CCHS = Canadian Community Health Survey.